Abstract：
UNASSIGNED: Obesity has been established as a significant risk factor for osteoarthritis. Anti-obesity medications (AOMs) have demonstrated efficacy in weight management. However, potential impact on osteoarthritis risk remains uncertain.
UNASSIGNED: This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.
UNASSIGNED: There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).
UNASSIGNED: AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.
UNASSIGNED: This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.
UNASSIGNED: There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).
UNASSIGNED: AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.
摘要：
■肥胖已被确定为骨关节炎的重要危险因素。抗肥胖药物（AOM）已证明在体重管理中具有功效。然而,对骨关节炎风险的潜在影响仍不确定。
■这项回顾性队列研究使用了2022年11月至2024年7月的Kythera数据。使用AOM的肥胖患者通过替瑞沙肽的诊断和处方声明进行鉴定，塞马鲁肽,或利拉鲁肽在2023年11月1日至2024年31月之间，进行6个月的随访以评估OA风险。OA风险，使用Cox回归和倾向得分匹配进行分析，控制合并症和社会人口因素。
■有39,394例肥胖患者使用AOM（23,933司马鲁肽12,854替拉肽，2,607利拉鲁肽）和72,405不使用AOM。AOM使用者的调整后的骨关节炎风险比非使用者低27%(风险比(HR)=073,95%CI(0.67-0.79),p<0.01)。在AOM中，与semaglutide相比,tirzepatide与骨关节炎(OA)风险显著降低相关(HR=0.57,95%CI:0.50-0.65,p<0.0001).利拉鲁肽与替瑞哌肽相比，OA风险显著增高（HR=1.63，95%CI：1.23-2.15，p=0.0007）。
■使用AOM与OA的风险明显降低相关，可能是一种有效的肥胖管理干预措施。
■这项回顾性队列研究使用了2022年11月至2024年7月的Kythera数据。使用AOM的肥胖患者通过替瑞沙肽的诊断和处方声明进行鉴定，塞马鲁肽,或利拉鲁肽在2023年11月1日至2024年31月之间，进行6个月的随访以评估OA风险。OA风险，使用Cox回归和倾向得分匹配进行分析，控制合并症和社会人口因素。
■有39,394例肥胖患者使用AOM（23,933司马鲁肽12,854替拉肽，2,607利拉鲁肽）和72,405不使用AOM。AOM使用者的调整后的骨关节炎风险比非使用者低27%(风险比(HR)=073,95%CI(0.67-0.79),p<0.01)。在AOM中，与semaglutide相比,tirzepatide与骨关节炎(OA)风险显著降低相关(HR=0.57,95%CI:0.50-0.65,p<0.0001).利拉鲁肽与替瑞哌肽相比，OA风险显著增高（HR=1.63，95%CI：1.23-2.15，p=0.0007）。
■使用AOM与OA的风险明显降低相关，可能是一种有效的肥胖管理干预措施。
